Laura Bonnell always knew she wanted to be a news reporter. And throughout her entire career she was always on the hunt for answers. […]
Cystic Fibrosis Awareness Month: A patient advocate’s story Read More »
The Administration’s Council of Economic Advisors (CEA) has released an analysis of savings expected from its “Most Favored Nation” deals with pharmaceutical manufacturers, but
Exaggerated MFN cost-saving estimates imperil U.S. innovation and investment Read More »
Recent medical breakthroughs are enabling better diagnostics for prostate cancer and Alzheimer’s and improving real-time imaging of tumors during surgery. The researchers behind these
Bayh-Dole Coalition report highlights eight American Innovators Read More »
Key takeaway: PDUFA enables the FDA to collect user fees from the biopharmaceutical industry, allowing for efficient and more predictable reviews. This funding model
What is PDUFA—and why does it matter for biotech innovators, FDA & patients? Read More »
When a biotech firm sells investors on the promise of a new drug, what they are really selling is the intellectual property behind their
BIO is expanding its work to defend IP Read More »
Since its founding in 1920, the National Health Council (NHC) has brought diverse organizations together to forge consensus and drive patient-centered health policy in
Q&A with National Health Council: Driving patient-centred policy Read More »
“Biotechnology innovation is advancing at an unprecedented pace, delivering new treatments and cures that offer long-awaited hope to patients and their families,” said Karin
BIO Coffee Chat: Price controls like MFN harm access, increase costs Read More »
Strong intellectual property protections sustain biotechnology innovation by enabling the investment needed to develop new medical breakthroughs. In comments submitted for the 2026 U.S.
BIO’s comments for USTR report highlight global threats to intellectual property Read More »
A year after a congressional commission urged strategic action to prevent China from replacing America as the world leader in biotechnology, we still have
BIO CEO hails congressional report on threat of China dominating biotech Read More »
The inaugural BIO Investment and Growth (BIG) Summit was a chance for leaders in the biotech industry to catch up on domestic and international
BIG Summit themes: Resilient investment, MFN threat, patients in the center Read More »
